Frontlight ResearchEarly access
Taking peopleNo phase
Vivinex Impress XY1-EM vs RayOne EMV
Key facts
- Who runs it
- Medical University of Bialystok
- Where
- Poland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 1 Jan 2026
- Expected to end
- 1 Jun 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- RayOne EMV
- Vivinex Impress
- Record updated
- 20 January 2026
Who can take part
- Age
- 21 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- age-related bilateral cataract
- age 21 or older
- visual acuity > 0.05
- axial length: 22.0 - 26.0 mm
- normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- written informed consent prior to surgery
Who cannot take part
- previous ocular surgery or trauma
- active ocular disease (e.g. chronic severe uveitis, proliferative diabetic retinopathy, chronic glaucoma not responsive to medication)
- relevant other ophthalmic diseases such as pseudoexfoliation syndrome (PEX), intraoperative floppy iris syndrome (IFIS)
- corneal decompensation or corneal endothelial cell insufficiency
- persons who are pregnant or nursing (pregnancy test will be taken in women of reproductive age)
- corneal astigmatism > 1 dpt
- retinopathies
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Comparison of the outcomes of bilateral implantation of extended depth of vision (EDOF) intraocular lenses (IOLs): the Rayone EMV and the Vivinex Impress XY1-EM in patients with cataract
The 2 groups in the trial
- Rayone EMVTreatment being tested
Patient will receive the non-diffractive monofocal IOL during cataract surgery
- Vivinex Impress XY1-EMTreatment being tested
Patient will receive the non-diffractive monofocal IOL during cataract surgery
Treatment: Vivinex Impress
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparison of Quality of Vision After Implantation of Monofocal Depth-enhanced Intraocular Lenses in Patients Undergoing Bilateral Cataract Surgery
- Criteria questions
- Built from NCT06891092, who can take part
- Record updated
- 20 January 2026